Q2 2025 Champions Oncology Inc Earnings Call
title conversation.
As a result of these projections and the expected data revenue, revenue growth for fiscal 2025 should be at least between 10 and 15 percent, and our quarterly adjusted EBITDA will remain positive. It should create value for our shareholders.
We look forward to our next update in mid-March when we report our third quarter.
Speaker Change: Thank you. At this time we will be conducting a question and answer session.
Speaker Change: If you would like to ask a question, please press star 1 on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star 2 if you'd like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys.
One moment, please, while we poll for questions.
Speaker Change: The first question comes from Matt Hewitt with Craig Hallam. Please proceed.
Speaker Change: Hello, this is Tal Kormanon from Matt Hewitt. First off, congratulations on the strong quarter. Could you please provide any color on the market dynamics? Other CROs are saying that there is some lumpiness in the funding environment. What are you seeing?
Speaker Change: Yeah, thank you for that question. Yeah, so we definitely, it's still,
Speaker Change: Not back to I would say where it was a couple years ago, but it's gotten better over the last year so I Guess the short answer is we are cautiously optimistic that the funding is coming back certainly from the big pharma there is
Speaker Change: funding from the biotech sector. There was definitely more investment in the biotech sector. It's not where it was
Speaker Change: a couple of years ago, but we are starting to see it opening up and we are starting to see signs that it is improving.
Speaker Change: Thank you. And then, are there any new tests or services you could be rolling out to drive further growth?
Speaker Change: that we have created from the beginning of the company. We always knew that the data we were creating was very unique from a biological perspective. And where I think for many years people were.
Speaker Change: focused on longitudinal data, so they would be interested in 100,000 patients who have RNA expression or some type of expression of a gene. We were always focused on adding
Speaker Change: and on and on just to try to understand the tumor and what was making the tumor turn on and off. And we did that for many, many, many tumors. So we went very deep where everyone else went long. And I think that
Speaker Change: We're at the right time now where everyone's interested in those type of data sets, and those are the type of data sets that are going to provide a lot of value going forward. So from that perspective, we feel like that's, you know...
Speaker Change: area where we're going to where there there's going to be growth and we're going to
Speaker Change: focus on that area. In terms of our other core business, those continue to be strong businesses. There's a lot of interest in both in vivo and ex vivo studies and biomarker studies and that's the bread and butter of what we do.
Thank you.
Speaker Change: Okay, we have no further questions in queue. I'd like to turn the floor back to management for any closing remarks.
Speaker Change: Okay, thank you. Thank you very much for joining us for a quarterly earnings call. We're excited about the progress we're making both on the core business...
Speaker Change: and the data strategy as well as the drug development subsidiary. So we feel very confident about the growth of the company and we are excited to give the next update in 90 days. So thank you and have a good evening.